KCPG
XERS icon

Kavar Capital Partners Group’s Xeris Biopharma Holdings XERS Stock Holding History

Kavar Capital Partners Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,000
Closed -$27.7K – 162
2023
Q1 		$27.7K Buy
+17,000
New +$21.3K 0.01% 161

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Kavar Capital Partners Group's XERS Position: Q2 2023 in Review

Kavar Capital Partners Group sold out of Xeris Biopharma Holdings (XERS) in Q2 2023, closing a stake of 17,000 shares — an estimated $27.7K sold.

Kavar Capital Partners Group first reported a position in XERS in Q1 2023 and held it in 1 quarter. The position peaked at $27.7K in Q1 2023. 102 funds tracked by Wall St. Rank hold XERS as of Q2 2023.

  • Kavar Capital Partners Group reported no remaining Xeris Biopharma Holdings position as of Q2 2023 after selling out during the quarter.
  • Kavar Capital Partners Group sold 17,000 Xeris Biopharma Holdings shares in Q2 2023, an estimated $27.7K.
  • Kavar Capital Partners Group first reported a position in Xeris Biopharma Holdings in Q1 2023 and held it in 1 quarter.
  • Kavar Capital Partners Group's Xeris Biopharma Holdings position peaked at $27.7K in Q1 2023.
  • 102 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2023.

Based on Kavar Capital Partners Group's 13F filing for Q2 2023, filed 7 Aug 2023.